The degree of intrinsic and interpatient phenotypic heterogeneity and its role in 2 tumour evolution is poorly understood. Phenotypic divergence can be achieved via 3 the inheritance of alternative transcriptional programs 1,2 . Cell-type specific 4 transcription is maintained through the activation of epigenetically-defined regulatory 5 regions including promoters and enhancers 1,3,4 . In this work, we annotated the 6 epigenome of 47 primary and metastatic oestrogen-receptor (ERα)-positive breast 7 cancer specimens from clinical samples, and developed strategies to deduce 8 phenotypic heterogeneity from the regulatory landscape, identifying key regulatory 9 elements commonly shared across patients. Highly shared regions contain a unique 1 Breast cancer (BC) is the most common cancer type and the second most frequent 2 cause of cancer related death in women 5 . 70% of all BC cases contain variable 3 amounts of oestrogen receptor-alpha (ERα) positive cells. ERα is central to BC 4 pathogenesis and serves as the target of endocrine therapies (ET) 6,7 . ERα-positive 5 BC is typically subdivided in two 'intrinsic' molecular subtypes (luminal A and luminal 6 B 8 ) characterized by distinct prognosis, highlighting functional inter-patient 7 heterogeneity. Recent analyses demonstrate that patient-to-patient heterogeneity is 8 more pervasive (reflected by histological 9 , genetic architecture 10 and transcriptional 11 9 differences) ultimately influencing long-term response to endocrine treatment 12 . 1 0 Indeed, 30-40% of ERα BC patients relapse during or after completion of adjuvant 1 1 endocrine therapies. At the time of relapse, almost all patients will have developed 1 2 resistance to ET, partly through treatment-specific genetic evolutionary trajectories 13 . 1 3
1 0 set of regulatory information including the motif for the transcription factor YY1. In 1 1 vitro work shows that YY1 is essential for ERα transcriptional activity and defines the 1 2 critical subset of functional ERα binding sites driving tumor growth in most luminal 1 3 patients. YY1 also control the expression of genes that mediate resistance to 1 4 endocrine treatment. Finally, we show that H3K27ac levels at active enhancer 1 5 elements can be used as a surrogate of intra-tumor phenotypic heterogeneity, and to YY1 motif is highly enriched in clonal enhancers identified in primary and metastatic 1 luminal patients ( Fig 2B) . All metastatic patients included in this study relapsed 2 following adjuvant endocrine therapies suggesting that YY1 might also play role in 3 this setting. In agreement, primary and metastatic samples show clonal YY1 4 enhancer activity, indicating that YY1 positive cells are not effectively cleared by the 5 therapy (Fig. 3A) . Therefore, we investigated the role of YY1 in LTED cells, an 6 MCF7-derivative that develop estrogen-independent growth partly through 7 constitutive activation of ERα signalling 16 . YY1 depletion leads to complete 8 abrogation of LTED growth demonstrating that YY1 is still required at this stage (Fig. 9 4G). Interestingly, LTED cells have an expanded repertoire of ERα binding 1 0 compared to MCF7, fuelled by endogenous ligands 13, 16 . The set of enhancers 1 1 engaged by ERα and YY1 in LTED cells is radically different compared to MCF7, transcription of genes involved with acquired endocrine therapy, suggesting that 1 5 during epigenetic reprogramming 16 , YY1 might stabilize ERα to LTED specific 1 6 enhancers ( Fig. 4J ). To further examine the relationship between YY1 and endocrine 1 7 resistance we analyzed a set of estrogen responsive genes whose transcription 1 8 cannot be antagonized by Tamoxifen treatment in MCF7 cells 58 . These genes were 1 9 not enriched for patient-private ERα, but we saw an ever-increasing association with 2 0
ERα-YY1 bound enhancers, especially with core ERα-YY1 ( Fig. 4K ). For example, 2 1 ERα-YY1 is found near CXXC5 and SLC9A3R1, ranked respectively first and second 2 2 as the most strongly estrogen-induced gene that cannot be antagonized by 2 3
Tamoxifen 58 . Collectively, these data strongly support the role of YY1 in ERα BC 2 4 growth and progression. cofactor. SLC9A3R1 null mice have disrupted protein-kinase-A-dependent cAMP-2 9 mediated phosphorylation 60 . In agreement with SLC9A3R1 potential role in 3 0 endocrine resistance, meta-analysis of patient-derived data using all available genes 3 1 (n=22,277) reveals that SLC9A3R1 expression is amongst the top 1% of genes with 3 2 1 5 the strongest prognostic association with relapse in a cohort of 724 ET-treated ERα-1 positive patients 39 (Fig. 5A ). High expression of SLC9A3R1 also significantly 2 correlates with poor survival in additional independent ERα-BC datasets 3 (Supplementary Figure 9A ). In addition to Tamoxifen treatment, SLC9A3R1 remains 4 transcriptionally active in most endocrine therapy resistant BC cell lines that retain 5 ERα expression (Supplementary Figure 9B clinically treated patients in vivo (Fig. 5B ). Overall, these data demonstrate that 1 1 SLC9A3R1 is a direct ERα target whose expression cannot be antagonized by first-1 2 line endocrine therapies. Figure 10A ). More importantly, TCGA RNA-seq analysis shows that SLC9A3R1 1 6 expression is higher specifically in ERα BC patients compared to normal tissue or 1 7 other subtypes (Supplementary Figure 10B ). Chromatin analyses of MCF7 and 1 8 LTED cells identify ER-bound enhancers at 3 independent loci within the insulated 1 9 SLC9A3R1 locus (E1-E3), a RD region directly looping to the YY1-bound SLC9A3R1 2 0 promoter within a CTCF insulated perimeter (Supplementary Figure 10C ). Strikingly, 2 1 E1 and E2 contain core ERα bindings in addition to YY1, while E3 contains a patient 2 2 unique ERα binding with no YY1 (Supplementary Figure 10C ). In vivo transcriptional 2 3 analysis demonstrates that SLC9A3R1 is the only gene near the E1-E2 enhancers 2 4 that shows a significant increase in bulk-RNA level when comparing normal breast 2 5 tissue with ERα-positive BC (Supplementary Figure 10D) . Interestingly, enhancer-2 6 activity appears to be immune to endocrine therapy (MCF7 vs. MCF7 tamoxifen 2 7 resistant and LTED, Supplementary Figure 10C ). Collectively, these data strongly 2 8 support the notion that SLC9A3R1 expression is driven by a breast cancer specific 2 9 enhancer within the expanding ERα-YY1 clone during tumor initiation. Nonetheless, 3 0 SLC9A3R1 expression is dependent on YY1 (Supplementary Figure 11A) , 3 1 demonstrating that both ERα and YY1 are essential for full enhancer activity.
2
Silencing SLC9A3R1 is sufficient to abrogate oestrogen-induced growth in ERα-3 3 1 6 positive cells ( Fig 5C) . Intriguingly, SLC9A3R1 is not essential for a second in ERα-1 positive model (T47D) but appears to be a critical gene for both AI-resistant cells 2 models ( Fig. 5C and Supplementary Figure S11B ). Collectively, these data 3 demonstrate that ERα-YY1 regulate SLC9A3R1 via enhancer binding and identify 4 SLC9A3R1 as a novel player involved in ET resistance.
6
Mapping phenotypic heterogeneity using YY1 and SLC9AR1 enhancer activity 7 Both SLC9A3R1 and YY1 enhancers are commonly activated in our patient's dataset 8 (SI=34 and SI=41 respectively). Yet, YY1 enhancer identifies YY1-positive cells as a 9 dominant clone in almost all patients (RI≤20, Fig 3A) . Conversely, SLC9A3R1 1 0 enhancer activity indicates that SLC9A3R1 marks a potentially dynamic sub-clonal 1 1 population in most primary patients (RI≥20, Fig 5D) . Our in vitro data suggest that 1 2 SLC9A3R1 transcription cannot be antagonized by endocrine therapies while evidence of a clonal SLC9A3R1 population was found in samples from three 1 6 metastatic, endocrine-resistant patients (Fig. 5D ).
7
Bulk transcriptional data show that average SLC9A3R1 expression is Figure 11C ). Of 2 3 note, the size of the sub-clonal population correlates with total RNA content for the 2 4 cells contained in both assays, suggesting that the decreasing bulk RNA signal is 2 5 driven by a progressively smaller subpopulation (Supplementary Figure 11C ). Similar Figure 12B ). Finally, to further validate that RI index can estimate 7 phenotypic clones, we retrospectively collected available FFPE biopsies for the BC 8 patients profiled with H3K27ac ChIP-seq (n=19). We then performed IHC using YY1 populations into phenotypical subclones. Tumor evolution studies have primarily focused on treatment naïve patients, taking 2 3 advantage of multi-regional sampling to retrospectively monitor changes in 2 4 clonality 14,62 . Clonal tracking is dependent in part on passenger mutations, and the 2 5 effect of therapy has been rarely accounted for 13,63 . More importantly, clonality has 2 6 been traced uniquely using genetic variants, with the intrinsic limitation of correlating glioblastoma cells shows that phenotypic clones might evolve independently from 3 0 mutational signatures 2 . In addition, the few studies that looked at driver mutations in 3 1 coding regions of primary and metastatic BC disease found relatively similar 3 2 1 8 mutational landscapes 15 , suggesting that mapping phenotypic clones though BC 1 progression might reveal new targets. Our ability to acquire qualitative estimates of 2 phenotypic clones using enhancer ranking provides for a potential approach for 3 tracking changes in tumor heterogeneity with the additional advantage of predicting 4 for potentially functional changes. We interrogated our patient's dataset focusing on 5 events occurring between treatment-naïve primaries and treatment-resistant 6 metastatic BC (Fig. 6A ). We hypothesized that phenotypic clonal evolution might be 7 driven by a coordinated activation/selection of groups of enhancers during BC 8 progression and this could be influenced by treatment. Our previous results suggest 9 that YY1+ cells remain clonal during progression ( Fig 3A) . Conversely, we show that 1 0 SLC9A3R1 expression is not antagonized by endocrine treatment suggesting that 1 1 SLC9A3R1-positive clones could expand during progression. We then calculated 1 2 changes in RI (ΔRI) for all enhancers captured in at least three patients (SI>3, 1 3 n=88935) between primary and metastatic samples ( Fig. 6B ). SLC9A3R1 ranks 1 4 amongst the enhancers with the strongest increase in predicted clonality going from response to treatment. To substantiate these data, we mapped the size of YY1 and 1 9 SLC9A3R1 phenotypic clones using IHC in an independent series of 20 matched 2 0 longitudinal biopsies. All surgical biopsies were obtained from treatment naïve 2 1 patients, while all the metastatic biopsies were taken at first relapse after endocrine 2 2 treatment 13 . We found YY1+ cells clonal both in primary and metastatic biopsies 2 3 ( Fig. 6D ). Conversely, SLC9A3R1+ subclones significantly expand during metastatic 2 4 progression to become completely clonal (100% staining) in 13/20 patients.
5
Interestingly, the only metastatic case in which we have observed a contraction of 2 6 the SLC9A3R1+ clone also showed a concomitant loss of ERα and PR positivity, To gain more insight on functional evolution, we systematically annotated all 1 regulatory regions based on bias in detection between primary and metastatic 2 patients ( Fig 6E) . As expected, the bulk of enhancers and promoters do not show 3 bias toward primary and metastatic BC patients (common enhancers, CE). However, 4 we could successfully identify two distinct sets of regulatory regions that are 5 preferentially associated with primary (primary enhancers, PE) or metastatic 6 (metastatic enhancers, ME) patients. Remarkably, while CE do not show stage-7 specific changes in RI, PE underlie larger sub-clonal populations in primary cancers 8 (statistically higher RIs in primary compared to metastatic, Fig. 6E ). Likewise, ME 9 have lower RI in metastatic samples suggesting that the number of cells carrying 1 0 these enhancers have increased during progression ( Fig. 6E ). We next explored the 1 1 potential causes and functional consequences driving these coordinated epigenetic 1 2 changes. We thus identified the potential transcriptional targets of our enhancers 1 3 taking in account CTCF boundaries 37 . Strikingly, we find that PE-associated gene-1 4 transcription is associated with significantly better outcome while ME-associated 1 5 gene-transcription in primary samples is associated with poor prognosis ( Fig 6D) .
6
These data imply that primary samples containing larger subpopulations of 1 7 phenotypic clones with metastatic features relapse earlier.
8
We then mined PE and ME regulatory regions to identify the associated generally correlates with the number of cells in a population carrying the specific 1 6 epigenetic information. Our predictions using YY1 and SLC9A3R1 enhancer fit 1 7 extremely well with experimental data derived from normal tissues or BC patients. showing that truncal (high allele frequency) mutations are also the most common 2 1 mutations within cancer cohorts.
2
The results described here have several practical implications for BC. First, by 2 3 comparing samples from drug-resistant metastatic patients with drug-naïve primary 2 4 samples, we uncovered a set of enhancers marking phenotypic clones that 2 5 significantly expand during breast cancer progression. Notably, these enhancers are 2 6 strongly associated with genes specifically transcribed in cells that acquire endocrine 2 7 therapy resistance ( Fig. 6H ). Conversely, enhancers progressively lost during tumour 2 8
progression are linked to processes that often occur early in tumorigenesis. A set of marked by an active FOXA1 enhancer and not via increased transcription of the 1 FOXA1 gene within single cells. It is tempting to speculate that this paradigm might 2 be valid for other genes. If correct it might signify that during cancer evolution, the 3 proportion of cells activating transcription is more important than the absolute 4 changes in transcription at the single cell levels. Interestingly, a set of enhancers 5 deactivated during progression involve IL-2 signalling (Fig. 6H ). Reduction in IL-2 6 signalling was identified as a potential marker of relapse 69 . Whether the IL-2 signal 7 source is the BC cells 70 themselves or it is due to a small contamination of immune 8 cells, needs to be defined. Equally, it will be important to measure real-time 9 activation/selection of enhancers in appropriate systems to ultimately establish if 1 0 phenotypic cancer evolution can be driven by Lamarckian events.
1
Finally, our analysis has identified two novel drivers of luminal BC. Firstly, we 1 2 identified YY1 as a key TF associated with clonal enhancers and promoters in BC 1 3 patients. Our data strongly support the idea that YY1 acts as a global co-activator in YY1 as the top hit, further supporting its potential role as enhancer gatekeeper 71 .
0
More specifically to ERα BC, we hypothesize that YY1 plays a critical role to stabilize 2 1 ERα binding at the transcriptionally productive core-ERα enhancers. Single-2 2 molecule imaging shows that estrogen activated ERα increases its residency time on 2 3 the chromatin 42 and recent evidence has shown that eRNA can trap YY1 on the 2 4 chromatin 49 . More importantly, enhancer co-occupancy for YY1 and ERα occurs 2 5 almost exclusively at highly shared-highly functional core-ERα bound loci.
6
Altogether, these data raise the intriguing hypothesis that YY1 might contribute to Intriguingly, SLC9A3R1 is amongst the strongest single prognostic genes for 6 relapse-free survival when considering endocrine treated patients (Fig. 5A ). An 7 attractive possibility is that YY1 stabilizes ERα sufficiently at the SLC9A3R1 8 enhancer maintaining epigenetic memory in the presence of external antagonists.
9
Future studies are required to investigate the exact mechanisms through which 1 0 SLC9A3R1 contribute to BC and efficient strategies to antagonize its transcription, ChIP-qPCR. Library preparation was performed using 10 -50 ng of 2 6 immunoprecipitated and Input samples. Briefly, reactions were carried out in 10 ul volume containing 5 ul of Sybergreen mix 1 (ABI; 4472918), 0.5 ul of primer (5 uM final concentration), 2.5 ul of genomic DNA 2 and 2 ul of DNASE/RNASE -free water. A three-step cycle programme and a 3 melting analysis were applied. The cycling steps were as follows: 10s at 95 oC, 30s 4 at 60 oC and 30s at 72 oC, repeated 40 times. and Atlas Antibodies Cat#HPA027247, RRID:AB_10601162 respectively) the 1 6
DHS imputations and TF motif analyses
following conditions were used. HPA9672 was diluted 1:400 and HPA27247 was 1 7
diluted 1:1500. Staining was automatized with a Ventana Benchmark Ultra using Healthcare Life Sciences; RPN3243) was used for chemiluminescent imaging using 1 the Fusion solo (Vilber; Germany) imager. E8875) or control treatment was administered and the cells incubated for 24 hours.
9
Cell lysates are then obtained using Passive lysis 5X buffer (Promega; E1941). The and allowed to shake for 30 minutes. Optical density was then measured using the 2 0
Sunrise microplate reader (Tecan; Sunrise) at 492 nm. Cell proliferation is then 2 1 calculated over the 7-day period using Day 0 as a baseline measurement. Overlap for ERα (in vivo) vs enhancers and promoters were calculated by betoold 2 5
intersect were the percentage overlap is calculated over the total number of Imperial Tissue bank. Sections were stained with YY1 or SLC9A3R1 antibodies.
Stained sections were divided in 20 sectors. 5 sectors with high tumor burden were ChIP-seq experiment (1=strongest, 100=weakest, binning on RPKM signal). Binning 1 7
Figure Legends
is repeated for each patient. D) Linear regression shows that clonal enhancers are indicates that BC-specific but not CRC-specific GWAS risk variants occur more 2 5
frequently than expected within the enhancers elements identified in our study. 
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